Clearside Biomedical Q4 2023 net loss narrows to $4.8M; cash runway to Q3 2025

Clearside Biomedical, Inc.

Net loss Q4 2023 of $4.8M ($0.08/shr) improved from $9.7M loss ($0.16/shr) in Q4 2022.
License revenue Q4 2023 of $6.3M, up from $0.3M, driven by $5M BioCryst upfront and $1M Aura milestone.
Cash $28.9M at Dec 31; subsequent $15M equity offering extends runway into Q3 2025.
Phase 2b ODYSSEY wet AMD trial topline data expected Q3 2024; randomization completed Dec 2023.
Full year 2023 net loss $32.5M ($0.53/shr) vs $32.9M ($0.55/shr) in 2022.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Clearside Biomedical, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $6.3 million, net income Net loss for the fourth quarter of 2023 was $4.8 million, EPS $0.08 per share.

Period: the fourth quarter and year ended December 31, 2023
Revenue: $6.3 million
Net income: Net loss for the fourth quarter of 2023 was $4.8 million
EPS: $0.08 per share
Result: reported results

Exact text from the filing

the first patient in the CoMpass trial in December 2023. Fourth Quarter 2023 Financial Results • License Revenue: License and other revenue for the fourth quarter of 2023 was $6.3 million, compared to $0.3 million for the fourth quarter of 2022. The $6.0 million increase was primarily attributable to the receipt of $5.0 million in an upfront license fee from

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-029956

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.